Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
- Autores
- Sookoian, Silvia Cristina; Pirola, Carlos José
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina - Materia
-
COMPLEX TRAITS
GENETICS
NONALCOHOLIC FATTY LIVER DISEASE
PRECISION MEDICINE
STEATOHEPATITIS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/117144
Ver los metadatos del registro completo
id |
CONICETDig_98a43c4a18a2260a19393aa6232c6e74 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/117144 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biologySookoian, Silvia CristinaPirola, Carlos JoséCOMPLEX TRAITSGENETICSNONALCOHOLIC FATTY LIVER DISEASEPRECISION MEDICINESTEATOHEPATITIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaKorean Association for the Study of the Liver2020-09-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/117144Sookoian, Silvia Cristina; Pirola, Carlos José; Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology; Korean Association for the Study of the Liver; Clinical and Molecular Hepatology; 26; 4; 10-9-2020; 461-4752287-27282287-285XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.e-cmh.org/journal/view.php?doi=10.3350/cmh.2020.0136info:eu-repo/semantics/altIdentifier/doi/10.3350/cmh.2020.0136info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:06:53Zoai:ri.conicet.gov.ar:11336/117144instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:06:53.769CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
title |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
spellingShingle |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology Sookoian, Silvia Cristina COMPLEX TRAITS GENETICS NONALCOHOLIC FATTY LIVER DISEASE PRECISION MEDICINE STEATOHEPATITIS |
title_short |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
title_full |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
title_fullStr |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
title_full_unstemmed |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
title_sort |
Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology |
dc.creator.none.fl_str_mv |
Sookoian, Silvia Cristina Pirola, Carlos José |
author |
Sookoian, Silvia Cristina |
author_facet |
Sookoian, Silvia Cristina Pirola, Carlos José |
author_role |
author |
author2 |
Pirola, Carlos José |
author2_role |
author |
dc.subject.none.fl_str_mv |
COMPLEX TRAITS GENETICS NONALCOHOLIC FATTY LIVER DISEASE PRECISION MEDICINE STEATOHEPATITIS |
topic |
COMPLEX TRAITS GENETICS NONALCOHOLIC FATTY LIVER DISEASE PRECISION MEDICINE STEATOHEPATITIS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome. Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina Fil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina |
description |
Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-09-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/117144 Sookoian, Silvia Cristina; Pirola, Carlos José; Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology; Korean Association for the Study of the Liver; Clinical and Molecular Hepatology; 26; 4; 10-9-2020; 461-475 2287-2728 2287-285X CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/117144 |
identifier_str_mv |
Sookoian, Silvia Cristina; Pirola, Carlos José; Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology; Korean Association for the Study of the Liver; Clinical and Molecular Hepatology; 26; 4; 10-9-2020; 461-475 2287-2728 2287-285X CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.e-cmh.org/journal/view.php?doi=10.3350/cmh.2020.0136 info:eu-repo/semantics/altIdentifier/doi/10.3350/cmh.2020.0136 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Korean Association for the Study of the Liver |
publisher.none.fl_str_mv |
Korean Association for the Study of the Liver |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269978921795584 |
score |
13.13397 |